



ASX Announcement | 26 November 2025 AdAlta Limited (ASX:1AD)

Results of Annual General Meeting

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products advises that its Annual General Meeting was held today at 2.00 pm AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the proxies received in respect of each resolution are included in the attached summary.

All resolutions were carried with support of more than 98% of shares voted on all resolutions.

This ASX announcement has been authorised for release by Tim Oldham CEO & Managing Director of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham

CEO & Managing Director

P: +61 403 446 665

E: ir@adalta.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its ‘East to West’ strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)

Follow us on [LinkedIn](#)

Follow us on [X \(formerly Twitter\)](#)

Disclosure of Proxy Votes

AdAlta Limited

Annual General Meeting

Wednesday, 26 November 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	899,958,209	884,476,267 98.28%	12,014,009 1.33%	0	3,467,933 0.39%	887,944,200 98.67%	12,014,009 1.33%	0	-
2 Re-election of Director, Ms Michelle Burke	P	900,449,769	889,799,152 98.82%	7,182,684 0.80%	0	3,467,933 0.39%	893,811,127 99.20%	7,182,684 0.80%	0	Carried
3 Renewal of Shareholder approval of Omnibus Equity Plan	P	899,749,302	887,572,994 98.65%	8,708,375 0.97%	208,907	3,467,933 0.39%	891,040,927 99.03%	8,708,375 0.97%	208,907	Carried
4 Ratification of prior issue of Placement Shares to New Life Sciences Capital, LLC (71,111,111 Shares)	P	885,826,157	874,117,894 98.68%	8,240,330 0.93%	476,955	3,467,933 0.39%	878,129,869 99.07%	8,240,330 0.93%	476,955	Carried
5 Ratification of prior issue of Placement Shares to New Life Sciences Capital, LLC (76,666,667 Shares)	P	885,826,157	873,934,894 98.66%	8,423,330 0.95%	476,955	3,467,933 0.39%	877,946,869 99.05%	8,423,330 0.95%	476,955	Carried
6 WITHDRAWN - 10 for 1 share consolidation	-	Resolution withdrawn								-
7 Approval and ratification of issue of share and options pursuant to 13 October 2025 placement	P	744,887,013	738,562,375 99.15%	2,790,330 0.37%	476,955	3,534,308 0.47%	742,640,725 99.63%	2,790,330 0.37%	476,955	Carried
8 Approval and ratification of issue of shares and options pursuant to 20 October 2025 up to \$1.1 million placement	P	680,395,923	674,121,285 99.08%	2,740,330 0.40%	468,045	3,534,308 0.52%	678,199,635 99.60%	2,740,330 0.40%	468,045	Carried



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval and ratification of issue of shares and options to 62 Capital Pty Ltd in connection with the up to \$1.1 million placement	P	835,481,724	829,207,086 99.25%	2,740,330 0.33%	468,045	3,534,308 0.42%	833,285,436 99.67%	2,740,330 0.33%	468,045	Carried
10 ASX Listing Rule 7.1A (Approval of Additional 10% Placement Capacity)	P	899,981,724	893,073,461 99.23%	3,440,330 0.38%	468,045	3,467,933 0.39%	897,085,436 99.62%	3,440,330 0.38%	468,045	Carried

